PEDIATRICS Vol. 42 No. 6 December 1968, pp. 980-985
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kempe, C. H.
Right arrow Articles by Shinefield, H.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Kempe, C. H.
Right arrow Articles by Shinefield, H.

SMALLPOX VACCINATION OF ECZEMA PATIENTS WITH A STRAIN OF ATTENUATED LIVE VACCINIA (CVI-78)

C. Henry Kempe M.D.1, Vincent Fulginiti M.D.1, Mikio Minamitani M.D.1, and Henry Shinefield M.D.1

1 Department of Pediatrics, University of Colorado Medical Center and the Department of Pediatrics, Permanente Foundation, San Francisco

A group of 1,009 patients suffering from eczema or other skin disorders have received elective vaccination with the CVI-78 strain of vaccinia. The vaccine is attenuated by repeated passages through chick embryos; its infectivity titer is 8.4 (TCID50/ml). It is free of bacteria and known viruses, including avian leukosis virus. It was administered by one of two routes (multiple pressure or subcutaneously) with a minimal dose of 1,000 TCID50 and a maximal dose of 30,000 TCID50. Local and systemic reactions and temperature elevations in these eczematous patients were significantly less marked than those experienced with a standard strain of vaccinia in normal children. No virus dissemination or other complications occurred, except for two instances of mild erythema multiforme. Seroconversion was noted in all 387 patients tested to date. Multiple pressure revaccinations with a standard strain 1 to 6 months later resulted in marked modification of the vaccination reaction without systemic reactions. It would appear that the CVI-78 strain of vaccinia virus is effective and safe for elective primary vaccination of children suffering from eczema.

Submitted on April 22, 1968
Accepted on July 14, 1968




This article has been cited by other articles:


Home page
 Proc. Natl. Acad. Sci. USAHome page
M. Kidokoro, M. Tashiro, and H. Shida
Genetically stable and fully effective smallpox vaccine strain constructed from highly attenuated vaccinia LC16m8
PNAS, March 15, 2005; 102(11): 4152 - 4157.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
L. H. McCurdy, J. A. Rutigliano, T. R. Johnson, M. Chen, and B. S. Graham
Modified Vaccinia Virus Ankara Immunization Protects against Lethal Challenge with Recombinant Vaccinia Virus Expressing Murine Interleukin-4
J. Virol., November 15, 2004; 78(22): 12471 - 12479.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
I. M. Belyakov, P. Earl, A. Dzutsev, V. A. Kuznetsov, M. Lemon, L. S. Wyatt, J. T. Snyder, J. D. Ahlers, G. Franchini, B. Moss, et al.
Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses
PNAS, August 5, 2003; 100(16): 9458 - 9463.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
B. T. Ober, P. Bruhl, M. Schmidt, V. Wieser, W. Gritschenberger, S. Coulibaly, H. Savidis-Dacho, M. Gerencer, and F. G. Falkner
Immunogenicity and Safety of Defective Vaccinia Virus Lister: Comparison with Modified Vaccinia Virus Ankara
J. Virol., June 27, 2002; 76(15): 7713 - 7723.
[Abstract] [Full Text] [PDF]

Home page
 ScienceHome page
K. Hayashi, J. Rosenthal, and A. L. Notkins
Iodine-125--Labeled Antibody to Viral Antigens: Binding to the Surface of Virus-Infected Cells
Science, May 5, 1972; 176(4034): 516 - 518.
[Abstract] [PDF]